TNGX — Tango Therapeutics Share News
0.000.00%
Last trade - 00:00- $3.83bn
- $2.81bn
- $62.38m
Brief: Tango Therapeutics Presents Preclinical Data On Precision Oncology Programs
U.S. STOCKS ON THE MOVE-Baker Hughes, Cano Health, Ascendis
U.S. STOCKS ON THE MOVE- Lockheed Martin, Heska Corp, Teck Resources
Tango Therapeutics up on FDA nod for trial of cancer drug in humans
Tango Therapeutics falls on bigger Q4 loss
Brief: Tango Therapeutics Reports Fourth Quarter Results
Tango Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Tango Therapeutics Inc expected to post a loss of 35 cents a share - Earnings Preview
Brief: Tango Therapeutics Announces Limited Exposure To Silicon Valley Bank
Tango Therapeutics rises on human trial nod and orphan tag for cancer drugs
Brief: Tango Therapeutics Announces FDA Clearance Of Investigational NDA For TNG462
Tango Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Tango Therapeutics Reports Third Quarter 2022 Results
Tango Therapeutics Inc expected to post a loss of 32 cents a share - Earnings Preview
Tango Therapeutics Inc expected to post a loss of 32 cents a share - Earnings Preview
Brief: Tango Therapeutics Announces Presentation Of Preclinical Data On Prmt5 Inhibitors Tng908 And Tng462 In Three Abstracts Accepted At 34Th Eortc-Nci-Aacr Symposium On Molecular Targets And Cancer Therapeutics
Brief: Tango Therapeutics Inc Files For Mixed Shelf Of Upto $400 Million - SEC Filing
Brief: Tango Therapeutics reports Q2 results
Brief: Tango Therapeutics Added To Russell 2000, 3000 And Microcap Indexes